Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2014

01-06-2014 | Rebuttal Letter

Rebuttal to: Letter to the Editor by Robert Burton, in response to doi:10.1007/s10549-013-2794-5

Authors: Carolyn Nickson, Kate E Mason, Anne M. Kavanagh

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Login to get access

Excerpt

We refer to the letter by Robert Burton, written in response to our recent ecological study which found that screening participation by Australian women aged 70–74 years is associated with a reduced incidence of large (>15 mm) cancers and possibly cancers with nodal involvement without a concomitant increase in overall cancer incidence [1]. …
Literature
1.
Nickson C, Mason KE, Kavanagh AM (2014) Breast cancer screening of women aged 70–74 years: results from a natural experiment across Australia. Breast Cancer Res Treat 143(2):367–372PubMedCrossRef
2.
Australian Institute of Health and Welfare & National Breast Cancer Centre (2007) Breast cancer survival by size and nodal status in Australia. Australian Institute of Health and Welfare, Canberra
3.
Thursfield V, Farrugia H, Karahalios E, Giles G (2012) Cancer in survival Victoria 2012: estimates of survival for 2006–2010 (and comparisons with earlier periods). Cancer Council Victoria, Melbourne
4.
Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, ICBP Module 1 Working Group et al (2013) Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000–2007: a population-based study. Br J Cancer 108(5):1195–1208PubMedCentralPubMedCrossRef
5.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRef
6.
Burton RC, Bell RJ, Thiagarajah G, Stevenson C (2012) Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991. Breast Cancer Res Treat 131(3):949–955PubMedCrossRef
7.
White V, Pruden M, Giles G, Collins J, Jamrozik K, Inglis G, Boyages J, Hill D (2004) The management of early breast carcinoma before and after the introduction of clinical practice guidelines. Cancer 101(3):476–485PubMedCrossRef
8.
9.
Roder DM, Olver IN (2012) Do the benefits of screening mammography outweigh the harms of overdiagnosis and unnecessary treatment?–yes. Med J Aust 196(1):16PubMedCrossRef
10.
Nickson C, Mason KE, English DR, Kavanagh AM (2012) Mammographic screening and breast cancer mortality: a case-control study and meta-analysis. Cancer Epidemiol Biomarkers Prev 21(9):1479–1488PubMedCrossRef
Metadata
Title
Rebuttal to: Letter to the Editor by Robert Burton, in response to doi:10.1007/s10549-013-2794-5
Authors
Carolyn Nickson
Kate E Mason
Anne M. Kavanagh
Publication date
01-06-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-2952-4

Other articles of this Issue 2/2014

Breast Cancer Research and Treatment 2/2014 Go to the issue

Preclinical Study

Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy

Clinical Trial

A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes

Epidemiology

Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry

Clinical trial

Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling

Epidemiology

Birth size in the most recent pregnancy and maternal mortality in premenopausal breast cancer by tumor characteristics

Preclinical study

Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits